XML 30 R18.htm IDEA: XBRL DOCUMENT
v3.19.2

License, Clinical Trial and Sponsored Research Agreements (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2019
License, Clinical Trial and Sponsored Research Agreements |
Schedule of Research and development for licenses | For the three months and six months ended June 30, 2019 and 2018, the Company recorded the following expense in research and development for licenses acquired:
|  | For the three months ended June 30, |  | For the six months ended June 30,
($ in thousands) |  | 2019 |  | 2018 |  | 2019 |  | 2018
City of Hope |  |  |  |  |  |  |  |  |  |  |  |
CD123 |  | $ | — |  | $ | — |  | $ | 250 |  | $ | —
CS1 |  |  | 200 |  |  | — |  |  | 200 |  |  | —
Manufacturing |  |  | — |  |  | — |  |  | — |  |  | 75
Nationwide Children's Hospital - C134 |  |  | — |  |  | — |  |  | 200 |  |  | —
Total |  | $ | 200 |  | $ | — |  | $ | 650 |  | $ | 75
For the three months and six months ended June 30, 2019 and 2018, the Company recorded the following expense in research and development for sponsored research and clinical trial agreements:
|  | For the three months ended June 30, |  | For the six months ended June 30,
|  | 2019 |  | 2018 |  | 2019 |  | 2018
($ in thousands) |  |  |  |  |  |  |  |  |  |  |  |
City of Hope |  | $ | 500 |  | $ | 500 |  | $ | 1,000 |  | $ | 1,000
City of Hope - CD123 |  |  | 456 |  |  | 114 |  |  | 759 |  |  | 264
City of Hope - IL13Rα2 |  |  | 225 |  |  | 143 |  |  | 567 |  |  | 503
City of Hope - Manufacturing |  |  | 115 |  |  | 115 |  |  | 229 |  |  | 229
Fred Hutch - CD20 |  |  | 374 |  |  | 418 |  |  | 641 |  |  | 684
BIDMC - CRISPR |  |  | — |  |  | — |  |  | 69 |  |  | —
Total |  | $ | 1,670 |  | $ | 1,290 |  | $ | 3,265 |  | $ | 2,680

X
- References No definition available. + Details
Name: | mbio_LicenseAgreementDisclosureAbstract
Namespace Prefix: | mbio_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. Include also the amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. Include also the amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration